secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001193125-23-098482
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics COO Carrie Melvin departs effective April 11, 2023
------------------------------------------------------------------------

- Carrie Melvin ceased as COO effective April 11, 2023; severance benefits provided per employment agreement.
- Severance treated as involuntary not-for-cause termination, subject to release and restrictive covenants.
- No replacement named in the filing; succession plans not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523098482/0001193125-23-098482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523098482/d460755d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-098482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer